Published in Cancer Law Weekly, October 28th, 2006
MultiCell does work in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza. Currently, the market for therapies that address these diseases is estimated at $8 billion worldwide.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.